340 filings
Page 2 of 17
425
g6448
22 Sep 22
Business combination disclosure
4:41pm
8-K
ykqojlnc02u
22 Sep 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:36pm
425
gt2uy56z57w
16 Sep 22
Business combination disclosure
4:46pm
8-K
8ol4p8r5
16 Sep 22
Regulation FD Disclosure
4:42pm
8-K
oqyqzjnmyrf34 j4
12 Sep 22
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
4:34pm
425
f0afyim0r59d6 la9i5y
8 Sep 22
Business combination disclosure
4:33pm
8-K
xbpi9a8el1v2njim6
8 Sep 22
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
4:32pm
8-K
j401yq5q6sraq zjed
6 Sep 22
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
6:05am
DEFM14A
fjnoy
2 Sep 22
Proxy related to merger
4:10pm
425
zz91mn 9k
2 Sep 22
Business combination disclosure
6:34am
8-K
c9cm2hps52h
2 Sep 22
Other Events
6:30am
8-K
1zb1 kx4ho
26 Aug 22
Unregistered Sales of Equity Securities
4:30pm
425
uu86v h2w4u8ql
19 Aug 22
Business combination disclosure
4:17pm
8-K
t929m7w 9w
19 Aug 22
Entry into a Material Definitive Agreement
4:15pm
8-K
4w17a43l803 gb2ou6bk
12 Aug 22
Other Events
6:10am
8-K
3xqatpfe bh16kn
5 Aug 22
Material Change Report
4:25pm
8-K
ugubjy n8vl5uqbm
4 Aug 22
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:17pm
8-K
1p1ka17vm 6g86y9
1 Aug 22
Zymeworks Announces Participation in Upcoming Investor Conferences
6:48pm
8-K
lbgul0
25 Jul 22
Regulation FD Disclosure
4:06pm